The benzopyran compound obtained by cultivating a mangrove-derived strain,
Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for
[...] Read more.
The benzopyran compound obtained by cultivating a mangrove-derived strain,
Streptomyces xiamenensis strain 318, shows multiple biological effects, including anti-fibrotic and anti-hypertrophic scar properties. To increase the diversity in the structures of the available benzopyrans, by means of biosynthesis, the strain was screened for spontaneous rifampicin resistance (Rif), and a mutated
rpsL gene to confer streptomycin resistance (Str), was introduced into the
S. xiamenensis strain M1-94P that originated from deep-sea sediments. Two new benzopyran derivatives, named xiamenmycin C (
1) and D (
2), were isolated from the crude extracts of a selected Str-Rif double mutant (M6) of M1-94P. The structures of
1 and
2 were identified by analyzing extensive spectroscopic data. Compounds
1 and
2 both inhibit the proliferation of human lung fibroblasts (WI26), and
1 exhibits better anti-fibrotic activity than xiamenmycin. Our study presents the novel bioactive compounds isolated from
S. xiamenensis mutant strain M6 constructed by ribosome engineering, which could be a useful approach in the discovery of new anti-fibrotic compounds.
Full article
